TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00922740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study: NCT03657225
Drug: Utilization of the conventional circuit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of the mini CPB circuit to conventional circuit
Study: NCT00153972
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02215967
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Study: NCT03959969
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prescription given for forty tablets of ibuprofen 600 mg every 6 hours as needed for pain.
Study: NCT00168779
Drug: telmisartan 80 mg / hydrochlorothiazide 25 mg
Normalized name: TELMISARTAN 80 mg / HYDROCHLOROTHIAZIDE 25 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168779
Drug: valsartan 160 mg / hydrochlorothiazide 25 mg
Normalized name: valsartan 160 MG / hydroCHLOROthiazide 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00168779
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03447743
Drug: XR-NTX community location
Normalized name: Potassium cation
DrugBank: Potassium cation (DB01345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XR-NTX will be administered at the local health care clinic
Study: NCT02046603
Drug: DMARDs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.
Study: NCT02046603
Drug: Oral Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.
Study: NCT02046603
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate per investigator's discretion.
Study: NCT00325247
Drug: ZINC
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02461160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching TAK-915 suspension
Study: NCT02854527
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose
Study: NCT02854527
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
Study: NCT02390882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02390882
Drug: HIP1402 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulon high dose
Study: NCT02065076
Drug: Lactose with carob gum
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01480245
Drug: GSK2402968
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg/kg/week
Study: NCT02367976
Drug: rhprouk
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
Study: NCT01370031
Drug: Clenil® Modulite® via Volumatic™ spacer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
Study: NCT01370031
Drug: Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
Study: NCT02157324
Drug: ACP-319
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02315131
Drug: TV46017
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Study: NCT02315131
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT00006038
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00006038
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00473590
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00295997
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00295997
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06768619
Drug: Group 2: single-dose of reference formulation+single-dose of test formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.
Study: NCT01625091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
Study: NCT00445146
Drug: RTV
Normalized name: Accu-Chek SmartView Test Strips
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
Study: NCT00445146
Drug: ARV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
Study: NCT02552901
Drug: 0.1 mg/kg ICG Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: least efficacious dose
Study: NCT02552901
Drug: 0.5 mg/kg ICG dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: per package insert
Study: NCT00619723
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient matching the active medication in appearance.
Study: NCT03893630
Drug: Acetylsalicylic Acid 81 mg
Normalized name: 5-BROMO-2-ACETYLSALICYLIC ACID 81 mg ORAL TABLET, COATED [Cardioaspirina Tabletas con cubierta enterica]
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 81mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study: NCT03893630
Drug: Acetylsalicylic Acid 162 mg
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 162mg acetylsalicylic acid daily, initiated between 11 and 16 weeks of gestation and continued until 36 weeks of gestation.
Study: NCT02390947
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg p.o. qd
Study: NCT02579252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03857646
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipids start at 1 g/kg/day and advance by 1 g/kg/day to a maximum of 3 g/kg/day as tolerated by the the neonate.
Study: NCT03888066
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Study: NCT03786029
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Study: NCT01860235
Drug: Injectable anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
Study: NCT01860235
Drug: 2% Benzocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthetic - 200mg/g of 2% benzocaine
Study: NCT01860235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
Study: NCT03786029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Study: NCT03786029
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Study: NCT00030719
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03422874
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN9708 is a second-generation reversible proteasome inhibitor which shows greater oral bioavailability, improved pharmacokinetics and enhanced antitumor activity compared with bortezomib (VELCADE®).
Study: NCT04393441
Drug: 011516X (New Artificial Tear Formulation)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eye drops
Study: NCT04393441
Drug: Systane Ultra Multidose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eye drops
Study: NCT04393441
Drug: REFRESH PLUS®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical eye drops
Study: NCT03756103
Drug: SPH3127 tablet Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 50 mg, once daily for 8 weeks.
Study: NCT03756103
Drug: SPH3127 tablet Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 100 mg, once daily for 8 weeks.
Study: NCT03756103
Drug: SPH3127 tablet Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPH3127 tablet, a kind of renion inhibitor, 200 mg, once daily for 8 weeks.
Study: NCT01838850
Drug: CS8635 20/5/12.5mg and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.~Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.~Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day.
Study: NCT02371655
Drug: Faecal Tagging
Normalized name: Enterococcus faecalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
Study: NCT02371655
Drug: Bowel cleansing
Normalized name: Dulcolax Bowel Cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
Study: NCT03756103
Drug: SPH3127 tablet Placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SPH3127 tablet placebo, once daily for 8 weeks.
Study: NCT03516448
Drug: Gan Fu Le Tablets
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 Tablets，tid,po
Study: NCT03516448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg/d, 5days,ivgtt
Study: NCT01824381
Drug: amniotic membrane
Normalized name: Amniotic Membrane Human Ophthalmic Sheet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02856555
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to firsocostat orally once daily.
Study: NCT00005603
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005603
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005603
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005603
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00573261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
Study: NCT02872428
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: By infusion over 1 hour
Study: NCT00649194
Drug: Aciphex® Tablets 20 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg, single dose fed
Study: NCT03189017
Drug: ICP-022
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product is a white, round, uncoated tablet.
Study: NCT03189017
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a white, round, uncoated tablet.
Study: NCT00290641
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00840853
Drug: Benadryl and Tylenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients may be premedicated with Benadryl and Tylenol before receiving the injection of cells.
Study: NCT03598270
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume equivalent to 1200 mg of atezolizumab drug product. Intravenous Day 1
Study: NCT03598270
Drug: Pegylated liposomal doxorubicin (PLD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m². Intravenous. Day 1
Study: NCT03101748
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03101748
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03106818
Drug: bupivacain with magnesium sulphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
Study: NCT03282318
Drug: ASP6294
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study: NCT03282318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study: NCT01302847
Drug: DTG film-coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG film-coated tablets initial starting dose at \~1 mg/kg with a maximum dose of 50 mg; orally once daily. Participants weighing ≥ 35kg received the proposed dose of 50 mg of DTG film-coated tablets.
Study: NCT01302847
Drug: DTG granules for suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTG granules for suspension initial starting dose at \~0.64 mg/kg with a maximum dose of 32 mg; orally once daily.
Study: NCT03717896
Drug: 200mg IV thiamine in 50mL 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine 200mg IV every 12 hours for 2 days
Study: NCT03717896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mL 0.9% saline
Study: NCT03860857
Drug: Tau PET scan using MK-6240
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tau Positron Emission Tomography scan using radio tracer MK-6240
Study: NCT00233558
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01366131
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous repeating dose
Study: NCT00003131
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02983747
Drug: Medication Treatment(Loxoprofen Sodium tablets,M)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
Study: NCT00387777
Drug: Patch with centrally acting analgesic
Normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01403051
Drug: EFV/FTC/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
Study: NCT01403051
Drug: Placebo for calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
Study: NCT01769456
Drug: Emtricitabine/tenofovir (FTC/TDF (Truvada®))
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
Study: NCT00966472
Drug: Erlotinib + Rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
Study: NCT04641104
Drug: Thiamine 500 MG
Normalized name: thiamine 500 MG
DrugBank: Thiamine (DB00152)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A solution of 500 mg of Thiamine Hydrocloride in a solution of 100 ml of NaCl 0.9% will be administered post-cardiac surgery in patients with lactate levels ≥ 2 mmol / L in the first 6 hours post-ICU admission.
Study: NCT04641104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml of NaCl 0.9% will be administered in the placebo group.
Study: NCT00042601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
Study: NCT03280030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two capsules, were administered twice per day by mouth on day 8-21 during induction and consolidation phase; then on days 1-28 for 12 cycles in the continuation (post consolidation) phase.
Study: NCT01109446
Drug: Triamcinolonacetonid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
Study: NCT00613808
Drug: Nitric Oxide 200ppm Group B
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 ppm, 8hrs / day for 6 weeks
Study: NCT00678210
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 2 mg BID for 12 weeks
Study: NCT00678210
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 5 mg BID for 12 weeks
Study: NCT00678210
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 15 mg BID for 12 weeks
Study: NCT00678210
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, BID for 12 weeks
Study: NCT00615199
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration via oral route twice daily
Study: NCT00615199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration via oral route twice daily
Study: NCT03564158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01216735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 weeks
Study: NCT02077140
Drug: MDT-10013
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02077140
Drug: Standard of care for pain
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01025414
Drug: enteral nutrition
Normalized name: ENTERAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines